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neonates undergoing routine screening for
congenital hypothyroidism at a university
teaching hospital in Nairobi, Kenya: a cross
sectional study
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Abstract
Background: In order to accurately interpret neonatal thyroid function tests (TFTs), it is necessary to have population
specific reference intervals (RIs) as there is significant variation across different populations possibly due to genetic,
environmental or analytical issues. Despite the importance of RIs, globally there are very few publications on RIs for
neonatal TFTs primarily due to ethical and technical issues surrounding recruitment of neonates for a prospective
study. To the best of our knowledge, this is the first report from Africa on neonatal RIs for TFTs.
Methods: We used hospital based data largely derived from neonates attending the wellness clinic at the Aga Khan
University Hospital Nairobi (AKUHN) where screening for congenital hypothyroidism is routinely done. Specifically we
derived age and gender stratified RIs for free thyroxine (fT4) and thyroid stimulating hormone (TSH) which had been
analyzed on a Roche e601 analyzer from 2011 to 2013. Determination of reference intervals was done using a
non-parametric method.
Results: A total of 1639 and 1329 non duplicate TSH and fT4 values respectively were used to derive RIs. There was a
decline in TSH and fT4 levels with increase in age. Compared to the Roche RIs, the derived RIs for TSH in neonates
aged 0–6 days and those aged 7–30 days had lower upper limits and narrower RIs. The fT4 lower limits for neonates
less than 7 days and those aged 7–30 days were higher than those proposed by Roche. There was a significant
difference in TSH RIs between male and female neonates aged less than 15 days. No gender differences were seen for
all other age stratifications for both TSH and fT4. Appropriate age and gender specific RIs were subsequently
determined.
Conclusion: The AKUHN derived RIs for fT4 and TSH revealed similar age related trends to what has been published.
However, the differences seen in upper and lower limits across different age stratifications when compared to the
Roche RIs highlight the need for population specific RIs for TFTs especially when setting up a screening programme for
congenital hypothyroidism. We subsequently recommend the adoption of the derived RIs by the AKUHN laboratory
and hope that the RIs obtained can serve as a reference for the African population.
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Background
Several pediatric reference intervals (RIs) for thyroid func-
tion tests (TFTs) have been published [1–7]. The neonatal
RIs described in some of these studies were established on
the basis of relatively small numbers of subjects or using
analyzers with diverse measurement principles and analyt-
ical performance. For example, in earlier studies ultrasen-
sitive immunoassays were not used to measure thyroid
stimulating hormone (TSH) [3]. The use of TSH immuno-
assays that can accurately determine very low concentra-
tions has resulted in a change in published RIs and
resulted in the introduction of diagnoses such as subclin-
ical hyperthyroidism. Use of TSH assays with different test
methodologies has been shown to influence reported inci-
dence of congenital hypothyroidism (CH) [8]. Despite the
importance of screening for CH in the neonatal period,
there are very few studies that specifically address RIs in
this age group.
CH is one of the most common preventable causes of
mental retardation. Its overall incidence ranges from 1
in 3000 to 1 in 4000 newborn infants [9, 10]. The most
common cause of CH is a primary disorder of the thy-
roid gland where reduced function from dysgenesis or
dyshormonogenesis results in an increase in TSH con-
centration [11]. TFTs play an important role in screening
for CH before the onset of symptoms hence enabling the
institution of early treatment which has been associated
with better clinical outcomes [12]. The prevalence of CH
has been reported to have increased after the introduc-
tion of screening tests [13–15]. Several factors could
contribute to a variation in reported prevalence of CH
across different populations. Some of these factors in-
clude race and ethnicity [15]. Furthermore, the testing
algorithm adopted when screening for CH as well as the
RIs used can contribute to the variation in CH preva-
lence. Initially, many screening programs performed a
thyroxine (T4) test, with a follow-up TSH test on infants
with values below a specified T4 cutoff. This strategy
not only identified primary CH but was able to identify
neonates with secondary hypothyroidism. However, with
advancements in the sensitivity of TSH assays, there has
been a move towards the use of TSH as a screening test
[12]. This is because serum TSH has a log-linear rela-
tionship with circulating thyroid hormone levels with a
2-fold change in free thyroxine (fT4) producing a 100-
fold change in TSH [16]. Some programs have under-
taken pilot programs measuring both fT4 and TSH on
all newborns resulting in a higher diagnostic rate of con-
genital hypothyroidism [17].
It is recommended by the international federation of
clinical chemistry (IFCC) that RIs should be population-
specific and derived from a set of reference individuals
representative of a reference population [18]. The clinical
laboratory standards institute (CLSI) also recommends
derivation of RIs through a formal study where samples
are collected from a reference group comprising a
minimum of 120 individuals identified from a reference
population through probability sampling and use of non-
parametric statistical methods to derive RIs. It also recom-
mends transference or verification of RIs as an option in
the event that establishing population specific RIs is not
possible [19]. For a CH screening program, the laboratory
carrying out testing should use TFT cut offs derived from
the local population to ensure that they are appropriate
since misdiagnosis can easily result from the adoption of
inappropriate RIs.
At the Aga Khan University Hospital Nairobi (AKUHN),
TFTs are performed on the Roche e601 analyzer. The cut
offs recommended by Roche for fT4 and TSH in babies
less than 3 months of age were derived from only 223 and
222 babies respectively from Leipzig, Germany [20]. This
population was comprised of primarily a Caucasian popu-
lation which was quite different from the AKUHN popu-
lation which is largely comprised of black Africans.
We therefore set out to derive age and gender specific
neonatal RIs for fT4 and TSH at AKUHN and compare
them with the manufacturer’s intervals to determine
whether any differences existed.
Methods
Study site
The study was carried out at AKUHN which is a Joint
Commission International accredited (JCIA) 300 bed pri-
vate hospital. It is a not-for-profit institution that provides
both primary and tertiary health care services. It has state
of the art intensive care and high dependency units for
children and adults as well as a laboratory that has
attained International Organization for Standardization
(ISO) 15189:2007 accreditation since July 2011. The hos-
pital also runs a number of general and specialized out-
patient clinics. Among these is the Well Baby Clinic
where infants are followed up. Since newborn screening is
not yet a policy in Kenya, the hospital routinely encour-
ages parents to have their babies screened for CH and
have blood samples drawn on the fourth or fifth day of
life, though some babies get screened later than this, but
still within the newborn period, for different reasons. For
pre-terms, routine screening for CH is only performed on
attainment of an age equivalent to a term baby. Data on
TSH and fT4 for neonates was obtained from the hospital
health management system from February 2011 to De-
cember 2013. Specifically, we extracted consecutive data
for all neonates who had fT4 or TSH done during the spe-
cified time period. Most of the neonatal TFTs are done as
part of routine screening for CH and it was thought that
this would serve as an ideal reference population assum-
ing that neonates attending a wellness clinic will most
likely be healthy. A neonate was defined as any newborn
Omuse et al. BMC Endocrine Disorders  (2016) 16:23 Page 2 of 8
30 days of age and below. This was used as a criterion
when extracting data from the hospital health manage-
ment system. File reviews were carried out only for neo-
nates with TSH or fT4 outside the Roche RIs so as to
identify and exclude from statistical analysis those with a
diagnosis of a thyroid disorder or an acute illness. Neo-
nates with both fT4 and TSH values outside Roche RIs
were excluded from the study.
Ethical approval
Informed consent from the patients whose laboratory data
was used was not required as this study was classified as a
clinical audit according to the hospitals research guide-
lines. Ethical waiver was obtained from the AKUHNs
health research ethics committee (2013/REC-15).
Thyroid function test determination
TFTs were carried out on the Roche e601 analyzer
(Roche diagnostic GmbH, Mannheim, Germany) which
uses the electro-chemiluminescence immunoassay
principle to determine the concentrations of fT4 and
TSH. Samples used were serum or plasma. The e601
TSH assay is a third generation immunoassay according
to the definition by Spencer et al. [21]. Its functional
sensitivity is 0.014 μIU/mL and limit of detection 0.005
μIU/mL. The coefficient of variation (CV) for fT4 was
1.97 % and 2.98 % at concentrations of 15.4 pmol/L and
55.3 pmol/L respectively. For TSH, the CVs were 2.64 %
and 2.42 % at concentrations of 3.4 μIU/mL and 13.6
μIU/mL respectively. Both the assays are enrolled for the
Randox International Quality Assessment Scheme
(RIQAS) and performance has been satisfactory over the
period for which the data was obtained.
Data analysis
Reference interval determination was performed using
Reference Value Advisor v2.1 (National Veterinary
School, Toulouse, France) [22]. This is a free set of Excel
macros that compute reference intervals from data con-
tained in a spreadsheet. It carries out both parametric
and non-parametric analysis for all data sets provided.
The non-parametric derived RIs that capture the mid
95 % of reference values were used to determine RIs for
this study. Initially, the data was stratified into 2 age
groups 0–6 days and 7–30 days to enable comparison
with Roche RIs. Subsequently, further age and gender
stratification was done and comparisons using Mann–
Whitney U test or Kruskal-Wallis H test were performed
to determine differences between groups. Median or
mean rank values were compared as appropriate. The
age-wise stratification for determining RIs was 0–7 days,
8–14 days, 15–22 days and 23–30 days. Comparisons
that showed no statistically significant difference after
the independent samples median test were grouped
together. Inferential statistical analysis was performed
using IBM International Business Machines Statistical
Package for the Social Sciences (IBM SPSS) Statistics for
Windows, Version 21.0. (Armonk, NewYork, IBM Cor-
poration). For all RIs, 90 % confidence limits were calcu-
lated for both the lower (2.5th percentile) and upper
limits (97.5th percentile). RIs were also determined using
standard and robust parametric methods to compare
with the non-parametrically derived RIs. This was done
on both untransformed data and data transformed using
the Box-Cox method. Testing for normality was done
using Anderson-Darling and a test for symmetry was
performed for the robust method. Outliers and suspect
data were determined using the Tukey’s method depend-
ing on whether values were less or greater than 3 times
the inter-quartile range (IQR) or 1.5–3 times the IQR
relative to the first and third quartiles. The Clinical La-
boratory Standards Institute (CLSI) guidelines for deter-
mining reference intervals were used for this analysis
[19]. P-values less than 0.05 were considered significant.
Results
A total of 1673 and 1359 non duplicate values for TSH
and fT4 respectively were obtained, however 34 TSH
and 30 fT4 values respectively were excluded after re-
view of 119 medical records and all TFT results. A total
of 29 patients had both fT4 and TSH values excluded.
The main reasons for exclusion included presence of an
acute illness such as neonatal sepsis or jaundice, both
fT4 and TSH values outside the Roche RIs and discrep-
ancies in age. Subsequently, 1639 TSH and 1329 fT4
values were used in determining RIs.
There was a general decline in TSH with increase in
age as shown in Fig. 1. The proposed Roche RIs for neo-
nates in the age group 0–6 days is 0.7–15.2 μIU/ml and
0.72–11.0 μIU/ml for the age group 7–30 days. Out of
632 neonates in the age group 0–6 days, 38 (6.0 %) fell
outside the Roche RIs, with 9 (1.4 %) having values
above the upper limit. In the age group 7 to 30 days, out
of 1009 neonates, 15 (1.5 %) fell outside the Roche refer-
ence limits with only 1 (0.1 %) having a value above the
upper limit.
Compared to the Roche RIs, the derived RI for TSH in
the 0–6 day age group was lower with narrower confi-
dence limits around the upper and lower limits as shown
in Fig. 2. For the 7–30 day old neonates, the derived RI
had a narrower spread and lower upper limit with nar-
rower confidence limits around the upper and lower
limits as shown in Fig. 2. Age stratified comparison of
medians showed no statistically significant difference be-
tween neonates aged 0–7 days and 8–14 days as well as
those aged 15–22 days and 23–30 days. These were sub-
sequently grouped into 0–14 days and 15–30 days re-
spectively for further analysis. There was a statistically
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significant difference in TSH mean ranks between neo-
nates aged 0–14 days and those aged 15–30 days (U =
312129, p = .029). There was a statistically significant dif-
ference in TSH mean ranks between male and female
neonates aged 0–14 days (U = 87542, p = .002). Age and
gender stratified TSH RIs are shown in Table 1.
The TSH RIs derived parametrically after data trans-
formation and exclusion of outliers were similar to the
non-parametrically derived RIs. However, most of the
data failed to normalize after Box-Cox transformation
hence the non-parametrically derived RIs were deemed
most appropriate.
For fT4, the suggested Roche RIs are 11.0–32.0 pmol/
L and 11.5–28.3 pmol/L for neonates in the age groups
0–6 days and 7–30 days respectively. Out of 515 neo-
nates in the age group 0–6 days, 43 (8.3 %) had values
outside the Roche RIs with all of them being above the
upper limit. In neonates aged 7–30 days, 6 out of 814
(0.7 %) had fT4 values outside the Roche RIs with 2
(0.6 %) having values below the lower limit. Four of the
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5 had corresponding TSH results with only 1 being
above the Roche upper limit.
There was a decline in fT4 levels with increase in age
as shown in Fig. 3. The upper and lower limits of the de-
rived RI for neonates less than 7 days old were higher
than the ones proposed by Roche. For neonates aged 7–
30 days, the derived RI had a higher lower limit and a
narrower interval compared to the one proposed by
Roche as shown in Fig. 4.
There was a statistically significant difference in the fT4
means across the 4 age stratifications. Gender-wise com-
parisons in the different age strata were not statistically
significant (x2(3) = 379.601, p = 0.000). RIs were subse-
quently derived for the different age strata as shown in
Table 2.
Discussion
There is scanty data on the prevalence of CH in Africa
most likely due to a greater focus on infectious diseases
which are major causes of morbidity and mortality in
children [23]. It is therefore not surprising that there is
scarce data on RIs for neonatal TFTs from the African
continent. To the best of our knowledge, this is the first
study to publish neonatal RIs for TFTs from Africa.
In order to avoid the lengthy and expensive process of
establishing RIs, many clinical laboratories adopt values
from in-vitro diagnostic company kit inserts, text books
or published literature. This is despite the possibility that
the populations used in deriving such RIs may be differ-
ent from the populations served by the respective la-
boratories. There are very few published studies on
neonatal RIs for TFTs partly due to the difficulty in en-
rolling neonates. The CALIPER study which was carried
out in Canada and has so far enrolled 8500 children
from birth to 18 years of age has established RIs for
many analytes including TFTs [24]. Carrying out a for-
mal RI study is extremely challenging given the need to
standardize all phases of the laboratory testing cycle and
the significant cost involved. In the absence of a formal
RI study, hospital data especially from a primary care
setting can be used as an alternative especially for tests
Table 1 AKUHN non-parametrically derived neonatal reference intervals for thyroid stimulating hormone (TSH)
Age (days) Number(gender) Lower Limit (μIU/mL) (90 % confidence limits) Median Upper Limit (μIU/mL) (90 % confidence limits)
0 to 14 415 (M) 0.59 (0.42–0.77) 3.31 12.84 (10.62–14.44)
0 to 14 479 (F) 0.56 (0.42–0.69) 2.74 11.00 (9.56–12.33)
15 to 30 359 (M) 0.90 (0.83–0.97-0.94) 2.71 7.46 (7.01–7.83)
386 (F)
Key: M Male, F Female
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that are performed routinely to screen for conditions
whose prevalence is not high [25–27]. Given that the
prevalence of CH is between 1 in 3000 to 1 in 10000
new born infants [9, 10, 28], most neonates screened for
CH would most likely be healthy and serve as appropriate
reference individuals. Zurakowski et al. used hospital data
collected between January 1993 and August 1996 to derive
RIs for T4, T3, TSH, and fT4. This data was obtained from
outpatient records at Children’s Hospital in Boston for pa-
tients 1 month through 20 years of age [3]. Kapelari et al.
carried out a similar study more recently using hospital
data from the Medical University Innsbruck in Austria for
children aged 1 day to 18 years of age [4].
In this study, we found 94 % and 98.5 % of TSH values
from AKUHN neonates aged 0–6 days and 7–30 days
respectively fell within the Roche RIs. For fT4, the per-
centages were 91.7 % and 99.3 % for the respective age
groups. When verifying RIs especially those derived from
a population that is dissimilar from your local popula-
tion, CLSI guidelines recommend that a laboratory can
accept them if 90 % of values derived from reference
individuals from the population served by the laboratory
fall within the RIs being verified [19].
The intent of CH screening programs is biased to-
wards detection of primary CH. Given the log linear re-
lationship of fT4 with TSH, measurement of TSH is
preferred as a cost effective approach to screening for
primary CH. A slight decline in fT4 results in a signifi-
cant rise in TSH allowing for the diagnosis of subclinical
hypothyroidism and possibly early intervention before
development of overt symptoms. There is marked vari-
ability in published neonatal TSH RIs most likely due to
differences in reference populations arising from genetic
or environmental factors. It is, therefore, important to
adopt population-specific cut offs for TSH so as to
optimize detection of primary CH. Compared to the
Roche RIs, both our TSH upper limits for neonates aged
0–6 days and 7–30 days were lower with narrower RIs.
Considering that the Roche RIs for TSH were derived
from only 223 neonates, our RIs derived from 1639 neo-
nates are more appropriate to the local population
served by our laboratory. A standard textbook of clinical
0
5
10
15
20
25
30
35
40
45
Roche 0-6 days
(n=112)
AKUHN 0-6 days
(n=515)
Roche 7-90 days
(n=111)
AKUHN 7-30 days
(814)
fT
4 
p
m
o
l/L
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Table 2 AKUHN non-parametrically derived neonatal reference intervals for free thyroxine (fT4)
Age (days) Number (gender) Lower Limit (pmol/L) Median Upper Limit (pmol/L)
(90 % confidence limits) (90 % confidence limits)
0 to 7 259 (M) 13.62 (12.98–14.16) 25.10 34.75 (33.64–35.67)
293 (F)
8 to 14 73 (M) 13.45 (10.68–15.44) 22.27 30.17 (27.93–32.18)
72 (F)
15 to 22 215 (M) 14.16 (13.26–14.63) 19.56 24.80 (23.98–25.48)
250 (F)
23 to 30 87 (M) 13.26 (12.23–13.90) 18.15 23.37 (22.39–26.64)
80 (F)
Key: M Male, F Female
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chemistry has proposed a TSH RI of 1.0–39 μIU/mL for
neonates less than 5 days of age and 1.7–9.1 μIU/mL for
those aged 2–20 weeks [5]. These are significantly differ-
ent from what we have derived and would therefore not
be ideal for our population. The TSH RI derived from
the CALIPER study for babies aged 4 days to 6 months
is 0.73–4.77 μIU/mL. This was obtained from 278 babies
with equal numbers of males and females and analysis
done on the Abbott Architect i2000 [24]. The low upper
limit for TSH published from the CALIPER study most
likely is a consequence of including babies as old as
6 months of age in the same group as neonates despite
the known decline in TSH and fT4 with increase in age
within the first year of life. Kapelari et al. determined a
TSH RI for neonates of 0.7–18.1 μIU/mL and demon-
strated a marked decline in TSH values in the neonatal
period very similar to what we have observed [4]. Unex-
pectedly, we found a significant difference in the distri-
bution and mean rank values between male and female
neonates aged 14 days and below. The female neonates
had a lower RI which is in keeping with a trend observed
by Zurakowski et al. for babies aged 1 year and above
[3]. Kapelari et al. found that males had higher mean
fT3 concentrations but no sex-differences were found
for TSH and fT4 between age-matched serum samples.
The observation of a significant gender wise difference
in mean rank values for TSH is therefore unique and
needs to be further investigated as an obvious explan-
ation is not forthcoming.
There was a general decline in fT4 values with in-
crease in age within the neonatal period which is in
keeping with what has been published previously [1, 2,
4, 24]. However, compared to the RIs provided by Roche,
our fT4 upper and lower limits for the age group 0–6
days are higher and more precise. For the age group 7–
30 days, the lower limit is higher and upper limit lower
giving a narrower interval than what is provided by
Roche [20]. As mentioned earlier, the Roche study that
determined fT4 RIs only included 223 babies compared
to 1329 in our study. Burtis et al. has published fT4 RIs
for neonates aged 1–4 days as 28.4–68.4 pmol/L and
10.3–25.8 pmol/L for those aged more than 2 weeks [5].
For neonates less than 7 days of age, the fT4 lower limit
was 13.62 pmol/L. This is significantly lower than what is
proposed by Burtis et al. and potentially would reduce the
number of neonates that would require unnecessary fol-
low up. In the CALIPER study, the fT4 RI for both male
and female neonates aged 5–14 days was 13.47–41.32
pmol/L and 8.71–32.53 pmol/L for those aged 15–29
days. The CALIPER study used values from 264 neonates
with equal numbers of males and females [24]. In our
study, the lower limit for fT4 for neonates aged 8–14 days
is 13.45 pmol/L which is very similar to the CALIPER
study. For neonates aged 15–22 days and 23–30 days, the
lower limits of 14.16 pmol/L and 13.26 pmol/L respect-
ively are higher than that derived for the CALIPER study.
We found no significant difference in RIs between
male and female neonates across all age stratifica-
tions. Zurakowski et al. found a significant difference
between males and females in T4 but not fT4 levels
though their study did not include neonates [3].
Djemli et al. found a significant difference in fT4
levels between males and females in the age group
15–17 years [1].
We do recommend the adoption of our derived RIs by
our laboratory and anticipate an increase in the number
of neonates found to have elevated TSH given the lower
upper limits. The age and gender wise stratification of
RIs will ensure that the interpretation of fT4 and TSH is
based on appropriate cut-offs that are sensitive to the
dynamic nature of TFTs within the neonatal period and
hopefully this will result in higher sensitivity for detec-
tion of CH.
Our study is limited by the fact that we used hospital
data without having well defined exclusion criteria to en-
sure that sick neonates or those with thyroid disorders
were not included. However, most of our data is from
neonates attending the wellness clinic which largely
comprises healthy neonates. We also reviewed medical
records for neonates with out-of-range values and ex-
cluded those with acute illnesses. None of the neonates
had a confirmed diagnosis of CH at the time of carrying
out the study though the follow up data was limited to a
maximum of 3 years as the review of medical records
was done in 2014. We also carried out parametric ana-
lysis to determine RIs after excluding outliers but found
no significant change. We therefore believe the non-
parametrically derived RIs are appropriate for our neo-
natal population.
Conclusion
This is the first study from Africa that has published
TSH and fT4 RIs for neonates and will go a long way in
providing a guide for the interpretation of TFTs espe-
cially when setting up a CH screening programme where
the target population is largely a black African popula-
tion. The differences seen when compared to other pub-
lished RIs may be reflective of a difference in reference
populations or analytical methodologies. More studies
from a similar population across the African continent
will help verify the findings of this study.
Abbreviations
AKUHN: Aga Khan University Hospital Nairobi; ANOVA: Analysis of variance;
CH: Congenital hypothyridism; CLSI: Clinical Laboratory Standards Institute;
fT3: free triiodothyronine; fT4: free thyroxine; IFCC: International Federation
of Clinical Chemistry; IQR: Inter Quartile Range; RI: Reference interval;
SPSS: Statistical Package for the Social Sciences; T4: Thyroxine; TFT: Thyroid
function test; TSH: Thyroid stimulating hormone.
Omuse et al. BMC Endocrine Disorders  (2016) 16:23 Page 7 of 8
Acknowledgement
None.
Funding
None.
Availability of data and materials
Not shared as it contains confidential patient data.
Authors’ contributions
GO conceived and designed the study, performed the data analysis and
drafted the manuscript. AK helped in the design of the study, data
collection, data analysis and drafting of the manuscript. FK helped in the
design of the study, data collection, data analysis and critical revision of the
manuscript. SH participated in data collection and critical revision of the
manuscript. ML participated in its design, coordination and critical revision of
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical waiver was obtained from the AKUHNs health research ethics
committee (2013/REC-15).
Author details
1Department of Pathology, Aga Khan University Hospital, P.O. Box
30270-00100, Nairobi, Kenya. 2Department of Paediatrics, Aga Khan University
Hospital, P.O. Box 30270-00100, Nairobi, Kenya.
Received: 16 December 2015 Accepted: 15 May 2016
References
1. Djemli A, Van Vliet G, Belgoudi J, Lambert M, Delvin EE. Reference intervals
for free thyroxine, total triiodothyronine, thyrotropin and thyroglobulin for
Quebec newborns, children and teenagers. Clin Biochem. 2004;37:328–30.
2. Lott JA, Sardovia-Iyer M, Speakman KS, Lee KK. Age-dependent cutoff values
in screening newborns for hypothyroidism. Clin Biochem. 2004;37:791–7.
3. Zurakowski D, Di Canzio J, Majzoub JA. Pediatric reference intervals for
serum thyroxine, triiodothyronine, thyrotropin, and free thyroxine. Clin
Chem. 1999;45:1087–91.
4. Kapelari K, Kirchlechner C, Hogler W, Schweitzer K, Virgolini I, Moncayo R.
Pediatric reference intervals for thyroid hormone levels from birth to
adulthood: a retrospective study. BMC Endocr Disord. 2008;8:15.
5. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and
Molecular Diagnostics. 4th ed. Missouri: Elsevier Inc.; 2006.
6. Elmlinger MW, Kuhnel W, Lambrecht HG, Ranke MB. Reference intervals
from birth to adulthood for serum thyroxine (T4), triiodothyronine (T3), free
T3, free T4, thyroxine binding globulin (TBG) and thyrotropin (TSH). Clin
Chem Lab Med. 2001;39:973–9.
7. Hubner U, Englisch C, Werkmann H, Butz H, Georgs T, Zabransky S, Herrmann
W. Continuous age-dependent reference ranges for thyroid hormones in
neonates, infants, children and adolescents established using the ADVIA
Centaur Analyzer. Clin Chem Lab Med. 2002;40:1040–7.
8. Hertzberg V, Mei J, Therrell BL. Effect of laboratory practices on the incidence
rate of congenital hypothyroidism. Pediatrics. 2010;125 Suppl 2:S48–53.
9. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir
CE, Mitchell ML, Hermos RJ, Waisbren SE, et al. Maternal thyroid deficiency
during pregnancy and subsequent neuropsychological development of the
child. N Engl J Med. 1999;341:549–55.
10. Waller DK, Anderson JL, Lorey F, Cunningham GC. Risk factors for congenital
hypothyroidism: an investigation of infant’s birth weight, ethnicity, and
gender in California, 1990–1998. Teratology. 2000;62:36–41.
11. Rastogi MV, LaFranchi SH. Congenital hypothyroidism. Orphanet J Rare Dis.
2010;5:17.
12. LaFranchi SH. Approach to the diagnosis and treatment of neonatal
hypothyroidism. J Clin Endocrinol Metab. 2011;96:2959–67.
13. Alm J, Larsson A, Zetterstrom R. Congenital hypothyroidism in Sweden.
Incidence and age at diagnosis. Acta Paediatr Scand. 1978;67:1–3.
14. Fisher DA. Second International Conference on Neonatal Thyroid Screening:
progress report. J Pediatr. 1983;102:653–4.
15. Harris KB, Pass KA. Increase in congenital hypothyroidism in New York State
and in the United States. Mol Genet Metab. 2007;91:268–77.
16. Andersen S, Bruun NH, Pedersen KM, Laurberg P. Biologic variation is
important for interpretation of thyroid function tests. Thyroid. 2003;13:
1069–78.
17. van Tijn DA, de Vijlder JJ, Verbeeten Jr B, Verkerk PH, Vulsma T. Neonatal
detection of congenital hypothyroidism of central origin. J Clin Endocrinol
Metab. 2005;90:3350–9.
18. Solberg HE. International Federation of Clinical Chemistry. Scientific committee,
Clinical Section. Expert Panel on Theory of Reference Values and International
Committee for Standardization in Haematology Standing Committee on
Reference Values. Approved recommendation (1986) on the theory of
reference values. Part 1. The concept of reference values. Clin Chim
Acta. 1987;165:111–8.
19. CLSI. Defining, establishing, and verifying reference intervals in the clinical
laboratory; approved guideline. In: Book Defining, establishing, and verifying
reference intervals in the clinical laboratory; approved guideline, vol. 28.
3rd ed. 2008.
20. Roche Diagnostics GmbH: Reference intervals for children and adults.
Elecsys Thyroid Tests. 2008
21. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance
goals for serum thyrotropin (TSH) assays. Clin Chem. 1996;42:140–5.
22. Geffre A, Concordet D, Braun JP, Trumel C. Reference Value Advisor: a new
freeware set of macroinstructions to calculate reference intervals with
Microsoft Excel. Vet Clin Pathol. 2011;40:107–12.
23. Child mortality, Millenium Development Goal (MDG) 4. [http://www.who.int/
pmnch/media/press_materials/fs/fs_mdg4_childmortality/en/]. Accessed 07
Dec 2015.
24. Bailey D, Colantonio D, Kyriakopoulou L, Cohen AH, Chan MK, Armbruster D,
Adeli K. Marked biological variance in endocrine and biochemical markers
in childhood: establishment of pediatric reference intervals using healthy
community children from the CALIPER cohort. Clin Chem. 2013;59:1393–405.
25. Harwood SJ, Cole GW. Reference values based on hospital admission
laboratory data. JAMA. 1978;240:270–4.
26. Kouri T, Kairisto V, Virtanen A, Uusipaikka E, Rajamaki A, Finneman H, Juva K,
Koivula T, Nanto V. Reference intervals developed from data for hospitalized
patients: computerized method based on combination of laboratory and
diagnostic data. Clin Chem. 1994;40:2209–15.
27. Yamakado M, Ichihara K, Matsumoto Y, Ishikawa Y, Kato K, Komatsubara Y,
Takaya N, Tomita S, Kawano R, Takada K, Watanabe K. Derivation of gender
and age-specific reference intervals from fully normal Japanese individuals
and the implications for health screening. Clin Chim Acta. 2015;447:105–14.
28. Zilka LJ, Lott JA, Baker LC, Linard SM. Finding blunders in thyroid testing:
experience in newborns. J Clin Lab Anal. 2008;22:254–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Omuse et al. BMC Endocrine Disorders  (2016) 16:23 Page 8 of 8
